Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 247

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Exosomal microRNA signatures in multiple sclerosis reflect disease status

Ebrahimkhani, Saeideh, Vafaee, Fatemeh, Young, Paul E., Hur, Suzy S. J., Hawke, Simon, Devenney, Emma, Beadnall, Heidi, Barnett, Michael H., Suter, Catherine M., Buckland, Michael E.·2017·Scientific Reports
DOI 10.1038/s41598-017-14301-3
Open this paper in CoChat — free account

Abstract

Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS). There is currently no single definitive test for MS. Circulating exosomes represent promising candidate biomarkers for a host of human diseases. Exosomes contain RNA, DNA, and proteins, can cross the blood-brain barrier, and are secreted from almost all cell types including cells of the CNS. We hypothesized that serum exosomal miRNAs could present a useful blood-based assay for MS disease detection and monitoring. Exosome-associated microRNAs in serum samples from MS patients ( n = 25) and matched healthy controls ( n = 11) were profiled using small RNA next generation sequencing. We identified differentially expressed exosomal miRNAs in both relapsing-remitting MS (RRMS) (miR-15b-5p, miR-451a, miR-30b-5p, miR-342-3p) and progressive MS patient sera (miR-127-3p, miR-370-3p, miR-409-3p, miR-432-5p) in relation to controls. Critically, we identified a group of nine miRNAs (miR-15b-5p, miR-23a-3p, miR-223-3p, miR-374a-5p, miR-30b-5p, miR-433-3p, miR-485-3p, miR-342-3p, miR-432-5p) that distinguished relapsing-remitting from progressive disease. Eight out of nine miRNAs were validated in an independent group ( n = 11) of progressive MS cases. This is the first demonstration that microRNAs associated with circulating exosomes are informative biomarkers not only for the diagnosis of MS, but in predicting disease subtype with a high degree of accuracy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41598-017-14301-3

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 39

  1. Nicholas, R. R. W. Multiple sclerosis. Multiple Sclerosis. Am Fam Physician 87, 712–714 (2013).
  2. Katz Sand, I. Classification, diagnosis, and differential diagnosis of multiple sclerosis. Curr Opin Neurol 28, 193–205 (2015). · DOI
  3. Housley, W. J., Pitt, D. & Hafler, D. A. Biomarkers in multiple sclerosis. Clin Immunol 161, 51–8 (2015). · DOI
  4. Zhou, X. & Yang, P. C. MicroRNA: a small molecule with a big biological impact. MicroRNA 1 (2012). · DOI
  5. Cheng, L., Sharples, R.A., Scicluna, B.J. & Hill, A.F. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell Vesicles 3 (2014). · DOI · Paper page
  6. Lee, J. Y., Park, J. K., Lee, E. Y., Lee, E. B. & Song, Y. W. Circulating exosomes from patients with systemic lupus erythematosus induce an proinflammatory immune response. Arthritis Res Ther 18, 264 (2016). · DOI
  7. Momen-Heravi, F. et al. Increased number of circulating exosomes and their microRNA cargos are potential novel biomarkers in alcoholic hepatitis. J Transl Med 13, 261 (2015). · DOI
  8. Pusic, A. D., Pusic, K. M. & Kraig, R. P. What are exosomes and how can they be used in multiple sclerosis therapy? Expert Rev Neurother 14, 353–5 (2014). · DOI
  9. McKay, K. A., Kwan, V., Duggan, T. & Tremlett, H. Risk factors associated with the onset of relapsing-remitting and primary progressive multiple sclerosis: a systematic review. Biomed Res Int 2015, 817238 (2015). · DOI
  10. Xiao, F. et al. miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res 37, D105–10 (2009). · DOI
  11. Chou, C. H. et al. miRTarBase 2016: updates to the experimentally validated miRNA-target interactions database. Nucleic Acids Res 44, D239–47 (2016). · DOI
  12. Sethupathy, P., Corda, B. & Hatzigeorgiou, A. G. TarBase: A comprehensive database of experimentally supported animal microRNA targets. RNA 12, 192–7 (2006). · DOI
  13. Ru, Y. et al. The multiMiR R package and database: integration of microRNA-target interactions along with their disease and drug associations. Nucleic Acids Res 42, e133 (2014). · DOI
  14. Lobb, R. J. et al. Optimized exosome isolation protocol for cell culture supernatant and human plasma. J Extracell Vesicles 4, 27031 (2015). · DOI
  15. Fenoglio, C. et al. Effect of fingolimod treatment on circulating miR-15b, miR23a and miR-223 levels in patients with multiple sclerosis. J Neuroimmunol 299, 81–83 (2016). · DOI
  16. Fenoglio, C. et al. Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. Multiple Sclerosis Journal 19, 1938–1942 (2013). · DOI
  17. Gandhi, R. miRNA in multiple sclerosis: search for novel biomarkers. Mult Scler 21, 1095–103 (2015). · DOI
  18. Gandhi, R. et al. Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis. Annals of Neurology 73, 729–740 (2013). · DOI
  19. Guerau-de-Arellano, M., Alder, H., Ozer, H. G., Lovett-Racke, A. & Racke, M. K. miRNA profiling for biomarker discovery in multiple sclerosis: from microarray to deep sequencing. J Neuroimmunol 248, 32–9 (2012). · DOI
  20. Junker, A. et al. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 132, 3342–52 (2009). · DOI · Paper page
  21. Keller, A. et al. Comprehensive analysis of microRNA profiles in multiple sclerosis including next-generation sequencing. Mult Scler 20, 295–303 (2014). · DOI
  22. Keren Regev, A. P. et al. Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis. Neuroimmunology & Neuroinflammation (2016). · DOI
  23. Lin, S. T. & Fu, Y. H. miR-23 regulation of lamin B1 is crucial for oligodendrocyte development and myelination. Dis Model Mech 2, 178–88 (2009). · DOI
  24. Fenoglio, C., Ridolfi, E., Galimberti, D. & Scarpini, E. MicroRNAs as active players in the pathogenesis of multiple sclerosis. Int J Mol Sci 13, 13227–39 (2012). · DOI
  25. Sarchielli, P. et al. Fibroblast growth factor-2 levels are elevated in the cerebrospinal fluid of multiple sclerosis patients. Neurosci Lett 435, 223–8 (2008). · DOI
  26. Aziz, F. The emerging role of miR-223 as novel potential diagnostic and therapeutic target for inflammatory disorders. Cell Immunol 303, 1–6 (2016). · DOI
  27. Iglesias, A. H. et al. Microarray detection of E2F pathway activation and other targets in multiple sclerosis peripheral blood mononuclear cells. J Neuroimmunol 150, 163–77 (2004). · DOI
  28. Igci, M. et al. Gene expression profiles of autophagy-related genes in multiple sclerosis. Gene 588, 38–46 (2016). · DOI
  29. Maciotta, S., Meregalli, M. & Torrente, Y. The involvement of microRNAs in neurodegenerative diseases. Front Cell Neurosci 7, 265 (2013). · DOI
  30. Boese, A. S. et al. MicroRNA abundance is altered in synaptoneurosomes during prion disease. Mol Cell Neurosci 71, 13–24 (2016). · DOI
  31. Lugli, G. et al. Plasma Exosomal miRNAs in Persons with and without Alzheimer Disease: Altered Expression and Prospects for Biomarkers. PLoS One 10, e0139233 (2015). · DOI · Paper page
  32. Alice Serafin, L. F. et al. and Christine Schwienbacher. Identification of a set of endogenous reference genes for miRNA expression studies in Parkinson’s disease blood samples. BMC research notes 7, 715 (2014). · DOI
  33. Kalinowska-Lyszczarz, A. & Losy, J. The role of neurotrophins in multiple sclerosis-pathological and clinical implications. Int J Mol Sci 13, 13713–25 (2012). · DOI
  34. Elovaara, I. U. M. et al. Adhesion molecules in multiple sclerosis: relation to subtypes of disease and methylprednisolone therapy. Arch Neurol. 57, 546–51 (2000). · DOI
  35. Fletcher, J. M., Lalor, S. J., Sweeney, C. M., Tubridy, N. & Mills, K. H. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin Exp Immunol 162, 1–11 (2010). · DOI
  36. McDonald, J. S., Milosevic, D., Reddi, H. V., Grebe, S. K. & Algeciras-Schimnich, A. Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem 57, 833–40 (2011). · DOI
  37. Lotvall, J. et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles 3, 26913 (2014). · DOI · Paper page
  38. Li, C. C. et al. Glioma microvesicles carry selectively packaged coding and non-coding RNAs which alter gene expression in recipient cells. RNA Biol 10, 1333–44 (2013). · DOI
  39. Seni, G. & Elder, J. F. Ensemble Methods in Data Mining: Improving Accuracy Through Combining Predictions. Synthesis Lectures on Data Mining and Knowledge Discovery 2, 1–126 (2010). · DOI

Cited by

See all 247

Metadata

Authors
Ebrahimkhani, S., Vafaee, F., Young, P. E., Hur, S. S. J., Hawke, S., Devenney, E., Beadnall, H., Barnett, M. H., Suter, C. M., & Buckland, M. E.
ORCID
Venue
Scientific Reports
Publisher
Springer Science and Business Media LLC
Published
2017-10-30
Volume
7
Issue
1
ISSN
2045-2322
DOI
10.1038/s41598-017-14301-3
Cited by
247
References
6
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.